IMO, STEM doesn't contend or compete with NVIV in any way.
STEM is a bounce play for me. To date, stem cell treatments haven't panned out in late stage trials (ATHX stage 2 recently for one) Given that STEM has no treatments in phase 3 as of yet, the hope is that they can actually show cause for phase 3 trials to happen sometime in the future...but that's a long way down the road.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.